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Abstract
We report a typical case of injection-site granuloma attributed to subcutaneous administration of
leuprorelin acetate, an LHRH agonist. A 70-year-old man who had undergone total prostatectomy
and was subsequently given leuprorelin injections for prostatic cancer presented with bilateral
nodules in the lower abdominal wall. An excisional biopsy revealed a non-caseous epithelioid
granuloma consisting of CD-68 positive histiocytic cells with infiltration of T-lymphocytes and
eosinophils; skin metastasis from prostatic adenocarcinoma was ruled out through histological and
immunohistochemical analysis. Generally, granulomas may be caused by delayed-type hypersensitivity
to the constituents of leuprorelin acetate injections.
Introduction
Although clinically localized prostatic cancer is treated by
prostatectomy or radiotherapy (external beam radiother-
apy or brachytherapy), endocrine therapy is chosen for
advanced or metastatic cancer because most prostatic
cancer cells depend on androgens for their growth. To
deprive of androgens, synthetic agonists of luteinizing
hormone-releasing hormone (LHRH) are administrated
instead of conducting an orchiectomy [1]. LHRH agonists,
after the initial transient flare-up of LH secretion, suppress
LH release and sex hormones by down-regulating the
receptors of gonadotrophs of the pituitary gland and
ablating androgens. Although decrease of libido and
osteopenia are well-known as the major side effects of
LHRH agonists, we describe a rare case of injection-site
granuloma (attributed to subcutaneous administration of
an LHRH agonist) and emphasize its importance since it
could mimic cancer metastasis, as in this case.
Case presentation
A 70-year-old Japanese man presenting with bilateral
subcutaneous nodules in the lower abdominal region was
referred to our hospital. He had undergone total prosta-
tectomy 6 months earlier and had then received monthly
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synthetic LHRH agonist. The bilateral nodules in the lower
abdomen were located at the sites of the leuprorelin
injections. The nodules were excised to rule out skin
metastasis from prostatic cancer.
Pathologic findings
Grossly, the well-circumscribed nodules, approximately
20 mm in diameter, were located in the upper dermis of
subcutaneous adipose tissue (Figure 1). Microscopically,
they were non-caseous granulomatous lesions with multi-
nucleated giant cells containing lipid droplets infiltrated
with lymphocytes and eosinophils (Figure 2A). Ziehl-
Neelsen, Periodic acid-Schiff (PAS) and Grocott staining
showed no bacterial, fungal or protozoan component.
Immunohistochemically, epithelioid cells were negative
for cytokeratin 7, cytokeratin 20, low molecular weight
keratin (CAM5.2) and prostate specific antigen (PSA),
indicating that metastasis from prostatic cancer could be
ruled out. Furthermore, epithelioid cells and multi-
nucleated giant cells positive for CD68 (Fig. 2B) were
histiocytic cells; infiltrating lymphocytes positive for CD-3
(Figure 2C), but negative for CD-20, were T-lymphocytes.
These findings suggested that the granulomas at the
injection sites were caused by delayed-type hypersensitiv-
ity to the leuprorelin acetate.
Discussion
Long-acting, synthetic LHRH agonists such as leuprorelin
and goserelin acetate have been widely used for advanced
Figure 1. Cross-section of the lesion excised from the right
lower abdomen. Epidermis covering the lesion (arrows) was
intact. The well-circumscribed nodules, 17 × 15 mm, were
located in the upper dermis to subcutaneous adipose tissue
(HE, X10).
Figure 2. Microscopic findings of non-caseous epithelioid
granulomatous lesion. (A): High-power view of the nodule
revealed epithelioid cells and multinucleated giant cells with
droplets (arrows) and infiltration of eosinophils and
lymphocytes (HE, X400). (B): Immunohistochemical staining
for CD-68. Epithelioid cells and multi-nucleated giant cells
were positive for CD-68. (C): Immunohistochemical staining
for CD-3. (counterstained with Hematoxylin, X400).
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are hot flashes, osteopenia and decreased libido due to
androgen deprivation. Injection-site granuloma is asso-
ciated with insulin and aluminum-containing tetanus
toxoid vaccines [3]. Injections of LHRH analogue rarely
cause skin lesion-mimicking metastasis of prostatic cancer
[4-6]. In this case, histological and immunohistochemical
analysis of the lesions at the injection sites ruled out skin
metastasis and infection by microorganisms. Granulomas
consisting of CD-68 positive histiocytes and CD3-positive
T lymphocytes were compatible with those seen in
delayed-type hypersensitivity reactions; droplet-containing
phagosomes were also observed in mono- and multi-
nucleated histiocytes. Since leuprorelin acetate is com-
bined with lactic acid, glycolic acid co-polymers or lactic
acid polymers, the formation of granulomas may be
related to the co-polymers or to the LHRH analogue itself.
Indeed, Manasco et al. have demonstrated that the
polymer, and not the diluent of leuprorelin acetate, elicits
a skin reaction, concluding that the causative agent is the
polymer [7]. Therefore, in prostatic cancer patients treated
with LHRH analogues, both the remission due to the
expansion of testosterone-insensitive clones and the
possible failure of leuprorelin administration because of
local skin reaction should be taken into consideration. In
summary, we reported a case of bilateral injection-site
granuloma by leuprorelin administration.
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